ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1417	National Cancer Institute	Html	en	Stomach (Gastric) Cancer Prevention (PDQ®)–Health Professional Version	Risk factors for stomach (gastric) cancer include certain health conditions (e.g., atrophic gastritis, pernicious anemia, H. pylori infection), genetic factors (e.g., Li-Fraumeni syndrome), or environmental factors (e.g., diet, smoking). Review the evidence on these and other risk factors and interventions to prevent stomach cancer in this expert-reviewed summary.	randomized placebo-controlled trial 0.595383 gastric adenomatous polyps 0.679902 experimental animal models 0.575229 infected family members 0.578256 antioxidant dietary supplements 0.574787 H. pylori 0.663672 annual incidence rates 0.588818 secondary prevention measures 0.572741 age-adjusted incidence rate 0.59463 statistically significant reduction 0.578799 combined antioxidant groups 0.572868 H. pylori infection 0.650947 high H. pylori 0.585004 family members 0.581961 gastric cancer mortality 0.686327 endoscopic resection techniques 0.578064 placebo group 0.585452 chemoprevention trial 0.590009 H. pylori-infected family 0.583244 Li Fraumeni syndrome 0.58425 intestinal metaplasia 0.628781 advanced premalignant lesions 0.570945 protective effects 0.575049 low selenium content 0.586292	statistically significant effect 0.623477 Beta Carotene trial 0.587524 United States 0.702911 gastric cancer incidence. 0.664051 precancerous gastric lesions. 0.647932 5-year survival rate 0.635247 gastric cancer cases 0.674324 gastric cancers 0.625749 gastrointestinal cancers 0.575893 H. pylori-infected people 0.581367 overall 5-year survival 0.57409 beta carotene 0.671292 small randomized trial 0.598139 gastric cancer 0.97116 gastric adenocarcinoma. 0.625249 eradication therapy 0.572355 Chinese medical journal 0.572216 vitamin supplementation 0.570623 statistically significant regression 0.573687 chronic atrophic gastritis 0.586209 gastric cancer. 0.610162 close family members. 0.576811 family history 0.58364 steady incidence rates 0.587586	CLICK HERE
1434	National Cancer Institute	Html	en	Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of chronic lymphocytic leukemia.	CLL 0.563454 German CLL Study 0.551069 monoclonal B-cell lymphocytosis 0.528403 Engl J Med 0.555252 trial 0.525679 leukemia group 0.552678 M. Prolymphocytic leukemia 0.545972 Routine chronic administration 0.534661 lymphocytic leukemia patients 0.591222 Leukemia group B. 0.542105 CLL Study Group 0.54078 cyclophosphamide 0.529502 Byrd JC 0.527428 Keating MJ 0.535835 advanced chronic 0.539233 patients 0.592663 Lymphocytic Leukemia Study 0.593872 T-cell prolymphocytic leukemia 0.546745 refractory high-risk chronic 0.534243 refractory chronic 0.528565 Adult Leukemia Group 0.542021 Leuk Lymphoma 0.531402 Lymphocytic Leukemia section 0.595648 fludarabine 0.547348 alemtuzumab versus fludarabine 0.527105	untreated B chronic 0.530625 et al. 0.648755 treatment 0.535273 small lymphocytic lymphoma 0.590269 French Cooperative Group 0.528743 German Chronic Lymphocytic 0.583925 Relapsed Chronic Lymphocytic 0.579501 acute myeloid leukemia 0.53754 stem cell 0.529413 Leukemia Study Group 0.55235 rituximab 0.530116 fludarabine-refractory B-cell chronic 0.53547 CLL therapy 0.52689 chronic lymphoid leukemia 0.573599 CLL Study Group. 0.526303 Abstract 0.627578 therapy 0.53011 Clin Oncol 0.713099 hairy cell leukemia 0.553353 blood 0.56117 chronic lymphocytic leukemia 0.965039 chronic lymphocytic leukaemia 0.705583 previously untreated patients 0.578343 allogeneic stem cell 0.525551	CLICK HERE
1584	National Cancer Institute	Html	en	Anal Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of anal cancer.	cancer treatment 0.433322 diagnose anal cancer 0.423593 Anal Cancer Treatment 0.419952 metastatic anal cancer 0.412176 Frequent anal redness 0.384126 body 0.434753 PDQ cancer information 0.446236 clinical trial search 0.504831 anal cancer spreads 0.410812 clinical trials 0.887836 cancer information summary 0.419039 clinical trial 0.647154 anus 0.449257 patients 0.429875 treatment clinical trial 0.380816 NCI PDQ cancer 0.384659 malignant tumor cells 0.380765 radiation therapy 0.718553 Treatment Editorial Board 0.382929 human immunodeficiency virus 0.375987 rectum 0.3805 General information 0.426863 general cancer information 0.376766 treatment 0.612453 abdominoperineal resection 0.403255	receptive anal intercourse 0.384527 new cancer treatments 0.377037 NCI-supported cancer 0.425485 cancer cells 0.46124 Cancer Information Service 0.376813 sphincter muscles 0.384557 treatment clinical trials 0.40741 National Cancer Institute 0.461854 Recurrent anal cancer 0.435676 new treatment 0.505194 external-beam radiation therapy 0.454262 IIIA anal cancer 0.402258 IIIB anal cancer 0.401297 anal cancer 0.792189 new treatment options 0.426789 anal opening 0.376839 cancer clinical trials 0.506964 stage 0.400723 Local resection 0.453758 tumor 0.401265 comprehensive cancer information 0.375327 internal radiation therapy 0.496063 cancer 0.970468 information 0.453326	CLICK HERE
1909	National Cancer Institute	Html	es	Tratamiento de la leucemia mielógena crónica (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de la leucemia mielógena crónica.	siguientes procedimientos 0.425256 células madre 0.845072 Chronic Myelogenous Leukemia 0.438357 leucemia linfoblástica aguda 0.438362 hueso compacto 0.417479 enlace drugs approved 0.436902 cromosoma filadelfia 0.526385 célula madre mieloide 0.437781 Sudores nocturnos 0.404959 células anormales.ampliar aspiración 0.417986 enlace medicamentos 0.404489 National Cancer Institute 0.403419 siguientes riesgos 0.40277	Instituto Nacional 0.405884 célula madre linfoide 0.438967 PDQ Tratamiento 0.410126 hijos.ampliar cromosoma filadelfia 0.412419 leucemia mielógena 0.99599 Physician Data Query 0.412686 laboratorio piezas 0.403757 leucemia mieloide aguda 0.437955 siguientes exámenes 0.405471 célula madre 0.512002 células sanguíneas maduras 0.448469 ósea elabora células 0.429135 siguientes sumarios 0.40998	CLICK HERE
1989	National Cancer Institute	Html	es	Cuidados médicos de apoyo en niños (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca de la peculiaridad de los asuntos que surgen durante y después del tratamiento en los niños con cáncer, y como sobrevivientes adultos de cáncer.	etapa final 0.974283 posibles efectos tardíos 0.445113 células madre 0.448459 adultos jóvenes 0.631616 personas jóvenes 0.478657 posibles tratamientos 0.424654 siguientes aspectos 0.421705 cáncer causa estrés 0.501532 apoyo social escaso 0.437899 siguientes tipos 0.415041 largo plazo 0.418906 efectos tardíos 0.530812 familia reaccionarán 0.418853 National Cancer Institute 0.415958 siguientes riesgos 0.411551	siguientes maneras 0.446878 Instituto Nacional 0.427962 síntomasEl trastorno 0.423462 Cuidado paliativo 0.412419 distintos miembros 0.413316 tratamiento ayuda 0.457106 suicidioUn número 0.419685 siguientes efectos 0.419968 posibles efectos 0.465562 Physician Data Query 0.458553 sistema nervioso central 0.433857 mayores probabilidades 0.421125 Estados Unidos 0.416849 mejores tratamientos 0.417691	CLICK HERE
2011	National Cancer Institute	Html	es	Exámenes de detección del cáncer de pulmón (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de las pruebas utilizadas para detectar o vigilar el cáncer de pulmón.	lung cancer screening 0.491865 Berg CD 0.308884 UK Lung Cancer 0.309828 Cooperative Early Lung 0.306877 Lung Cancer Study 0.310626 lung cancer 0.996403 Reduced lung-cancer mortality 0.308509 American Cancer Society 0.314872 Sloan-Kettering Lung Study 0.306329 Extended lung 0.305748 lung-cancer screening 0.305282 Lung Screening Trial 0.34779 Preventive Services Task 0.315666 early lung cancer 0.370281 Cancer Res 0.308506 screening results 0.305543 exámenes detección 0.3124 Screening Trial 0.41076 lung-cancer mortality with 0.308638 Randomized Danish Lung 0.306065 CT screening 0.322848 Natl Cancer Inst 0.348878 small lung 0.309116 Lung Cancer Risk 0.310447 from baseline screening 0.305357	More lung 0.305626 Screening Trial with 0.311542 early stage lung 0.306471 Is curable lung 0.306471 cytologic screening 0.312546 Hocking WG 0.305973 Hopkins Lung Project 0.306129 CT screening according 0.305575 Danish Lung Cancer 0.338861 Lung Cancer Action 0.32014 randomised danish lung 0.306155 National Lung Screening 0.345051 Intern Med 0.314222 lung cancer detection 0.362796 Services Task Force 0.31539 Randomized Lung Cancer 0.310797 from semi-annual screening 0.30542 PLCO Cancer Screening 0.310194 Mayo Lung Project 0.341943 lung cancers detected 0.306094 Memorial Sloan-Kettering 0.306282 Cancer Action Project 0.310925 Lung Project revisited 0.306785 Cancer Screening Trial 0.390805	CLICK HERE
3444	National Cancer Institute	Html	es	Exámenes de detección del cáncer de cavidad oral y orofaringe (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de cavidad oral y orofaringe.	Ramadas K 0.326456 Sankaranarayanan R 0.337876 accessed march 0.331249 Zhang L 0.310727 Clinical Preventive Services 0.308765 Interim results from 0.307724 Sin embargo 0.381657 Kerr AR 0.312561 American Cancer Society 0.427439 Early findings from 0.308051 CA Cancer 0.323169 cluster randomized controlled 0.308479 oral pre-malignant 0.326412 oral cancer 0.913191 Preventive Services Task 0.376173 Instituto Nacional 0.317765 Cancer Res 0.323621 Human papillomavirus infection 0.307515 PDQ Exámenes 0.32226 oral cancer screening 0.566684 Estados Unidos 0.310609 Morton TH Jr 0.307383 Morton TH 0.311837 Epstein JB 0.323025 Database Syst Rev 0.307163	visual screening 0.315772 screening with 0.315479 upper aerodigestive tract 0.307566 SEER Cancer Statistics 0.324889 Cancer Society guidelines 0.325639 Trivandrum Oral Cancer 0.343561 carcinoma versus lesiones 0.311231 Jacob BJ 0.31089 potentially malignant disorders 0.308445 Cancer Facts 0.324242 Long term effect 0.3078 adjacent to clinically 0.307949 Oral Oncol 0.526329 oral verrucous 0.325426 National Cancer Institute 0.351683 center grapples with 0.307601 Oral Pathol Med 0.361585 Screening Study Group 0.316915 Am Dent Assoc 0.308416 Services Task Force 0.375429 Fluorescence visualization detection 0.308258 detección versus atención 0.319469 Brief Evidence Update 0.307856 Poh CF 0.312257	CLICK HERE
3460	National Cancer Institute	Html	es	Coenzima Q10 (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso de la coenzima Q10 como tratamiento para las personas con cáncer.	Natl Acad Sci 0.506232 animal models 0.503048 Lockwood K 0.522246 Friend leukemia virus 0.50335 Mol Aspects Med 0.525442 Prog Drug Res 0.505422 Exp Clin Res 0.507107 Ernster L 0.506157 Clin Investig 0.504327 vitamina q10 0.508703 vitamin q10 0.549224 Health Syst Pharm 0.503499 Chem Pathol Pharmacol 0.515808 Bliznakov EG 0.512562 Hanioka T 0.504235 coenzyme q10 0.845306 with vitamin q10 0.522905 reticuloendothelial system upon 0.50329 Res Commun Chem 0.525595 coenzima q10 0.990386 Nylander M 0.503126 system upon stimulation 0.503357 coenzima q.10 0.50372 Coenzyme Q10 administration 0.515239 patients with 0.52239	Clinical Aspects 0.506167 Folkers K 0.720923 patients treated with 0.503528 Osterborg A 0.503093 coenzima q10 resumen 0.509859 Commun Chem Pathol 0.52121 Moesgaard S 0.509545 Biophys Res Commun 0.66246 Chemother Rep 0.503476 Nordenbrand K 0.502764 Proc Natl Acad 0.506461 Apparent partial remission 0.503092 Biochem Biophys Res 0.653978 with nutritional antioxidants 0.504649 coenzima q10 ayuda 0.51293 Drugs Exp Clin 0.50459 conzima q10 0.506965 Overvad K 0.504381 Clin Nutr 0.503026 serious deficiency 0.503488 coenzyme q10 concentrations 0.523415 radicales libres 0.504036 essential fatty acids 0.503269 Yamashita S 0.503124	CLICK HERE
15639	National Cancer Institute	Html	null	Grants	Learn about the different grants that are available, such as Research Projects Grants, SPORE Grants, career awards and cancer education grants, training grants, and others.			CLICK HERE
16842	National Cancer Institute	Html	en	Johns Hopkins University — Predoctoral and Postdoctoral Training Program in Nanotechnology for Cancer Research	The focus of the Johns Hopkins University Cancer Nanotechnology Training Center is presented here.	predoctoral fellows 0.736483 cancer nanobiotechnology 0.632531 optimal treatment 0.545276 Johns Hopkins University 0.729715 journal club 0.539106 novel cancer diagnostics 0.713403 program fosters 0.562779 steady state number 0.670018 epigenetic markers 0.560601 tumor boards 0.538166 NTCR program 0.576419 new frontier 0.564875 individual patient 0.643505 engineering/physics discipline 0.563571 physical sciences-oncology center 0.676488 lab course 0.540911 new modalities 0.563 cellular / cancer 0.59221 Johns Hopkins Institute 0.669855 dedicated annual symposium 0.651728 experimental facilities 0.538368 Vivo Cellular 0.548936 Molecular Imaging Center 0.688968 black-box input-output techniques 0.710638	scientific exploration 0.554225 clinical resources 0.5443 human diseases 0.555299 cancer cell functions 0.720912 clinical conferences 0.540551 high-throughput diagnostic tools 0.682779 non-viral delivery systems 0.686087 unique educational resources 0.657197 postdoctoral fellows 0.715577 Principal Investigator 0.564913 therapeutic tools 0.551025 Pancreatic Cancer Center 0.731915 Ludwick Center 0.581555 NTCR trainees 0.59515 cancer nanotechnology excellence 0.742492 outstanding trainees 0.578764 disease phenotype 0.55677 Comprehensive Cancer Center 0.727928 Cancer Genetics 0.585039 NTCR fellows 0.742981 engineer novel drug/antibody/siRNA 0.668859 human cancers 0.551276 core courses 0.541397 Training Focus 0.565904	CLICK HERE